Kategorie: investing
Nachricht
Neueste Nachrichten
Neueste Nachrichten
Anavex stock plummets 50% after Alzheimer's drug faces EU regulatory rejection
A once-promising Alzheimer's treatment hits a wall in Europe. Can Anavex recover from this regulatory blow—or is this the end of blarcamesine's potential?
The pacifier's turbulent history: from ancient clay to modern medical battles
From toxic lead-dyed rubber to orthodontic breakthroughs, this tiny object has divided doctors and parents for generations. The fight isn't over yet.
Baxter's bold restructuring spins off BioPharma to fuel core growth by 2027
A second major split in six years signals Baxter's bet on high-growth markets. Will this unlock value for investors and patients alike?
Gossamer Bio's seralutinib fails critical Phase 3 trial, sending stock into freefall
A failed trial leaves Gossamer Bio's future hanging by a thread. With shares near collapse, all eyes turn to the FDA for a lifeline.